Takeda Pharmaceutical Key Executives
This section highlights Takeda Pharmaceutical's key executives, including their titles and compensation details.
Find Contacts at Takeda Pharmaceutical
(Showing 0 of )
Takeda Pharmaceutical Earnings
This section highlights Takeda Pharmaceutical's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
May 08, 2025
Time:
Before Market
Est. EPS:
$-
Status:
Unconfirmed
Last Earnings Results
Date:
January 30, 2025
EPS:
$0.10
Est. EPS:
$25.86
Revenue:
$1.14T
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2025 | 2025-01-30 | $25.86 | $0.10 |
| Read Transcript | Q2 | 2025 | 2024-10-31 | $32.80 | $58.14 |
| Read Transcript | Q1 | 2025 | 2024-08-02 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-05-09 | $0.77 | $-2.01 |
| Read Transcript | Q3 | 2023 | 2024-02-01 | $28.50 | $67.59 |
| Read Transcript | Q2 | 2023 | 2023-10-26 | $36.44 | $-31.00 |
| Read Transcript | Q1 | 2023 | 2023-07-27 | $69.18 | $57.51 |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Healthcare
Drug Manufacturers - Specialty & Generic
$4552.00
Stock Price
$7.22T
Market Cap
-
Employees
Tokyo, None
Location
Financial Statements
Access annual & quarterly financial statements for Takeda Pharmaceutical, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $4.26T | $4.03T | $3.57T | $3.20T | $3.29T |
| Cost of Revenue | $1.43T | $1.24T | $1.11T | $994.31B | $1.09T |
| Gross Profit | $2.83T | $2.78T | $2.46T | $2.20T | $2.20T |
| Gross Profit Ratio | 66.43% | 69.11% | 69.00% | 68.91% | 66.89% |
| Research and Development Expenses | $729.92B | $633.33B | $526.09B | $455.83B | $492.38B |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.05T | $997.31B | $886.36B | $875.66B | $964.74B |
| Other Expenses | $834.44B | $-9.47B | $588.87B | $1.41T | $1.43T |
| Operating Expenses | $2.62T | $2.29T | $2.00T | $1.69T | $2.10T |
| Cost and Expenses | $4.05T | $3.54T | $3.11T | $2.69T | $3.19T |
| Interest Income | $11.29B | $62.91B | $23.70B | $105.52B | $27.83B |
| Interest Expense | $153.63B | $169.70B | $166.61B | $248.63B | $165.01B |
| Depreciation and Amortization | $728.00B | $664.40B | $583.15B | $559.67B | $583.65B |
| EBITDA | $874.60B | $1.18T | $1.18T | $983.72B | $880.33B |
| EBITDA Ratio | 20.51% | 30.02% | 29.49% | 36.73% | 20.90% |
| Operating Income | $214.07B | $490.50B | $460.84B | $509.27B | $100.41B |
| Operating Income Ratio | 5.02% | 12.18% | 12.91% | 15.93% | 3.05% |
| Total Other Income Expenses Net | $-161.28B | $-115.42B | $-158.27B | $-143.03B | $-161.16B |
| Income Before Tax | $52.79B | $375.09B | $302.57B | $366.24B | $-60.75B |
| Income Before Tax Ratio | 1.24% | 9.31% | 8.48% | 11.45% | -1.85% |
| Income Tax Expense | $-91.41B | $58.05B | $72.41B | $-9.94B | $-105.04B |
| Net Income | $144.07B | $317.02B | $230.06B | $376.00B | $44.24B |
| Net Income Ratio | 3.38% | 7.87% | 6.45% | 11.76% | 1.34% |
| EPS | $92.09 | $204.29 | $147.14 | $240.72 | $28.41 |
| EPS Diluted | $91.16 | $201.94 | $145.87 | $238.96 | $28.25 |
| Weighted Average Shares Outstanding | 1.56B | 1.55B | 1.56B | 1.56B | 1.56B |
| Weighted Average Shares Outstanding Diluted | 1.58B | 1.57B | 1.58B | 1.57B | 1.57B |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.14T | $1.18T | $1.21T | $1.05T | $1.11T | $1.04T | $1.06T | $956.16B | $1.10T | $1.00T | $972.47B | $873.29B | $901.29B | $844.82B | $949.60B | $770.27B | $836.75B | $788.93B | $801.85B | $771.70B |
| Cost of Revenue | $416.87B | $536.73B | $549.78B | $569.25B | $379.48B | $343.58B | $321.11B | $309.77B | $335.97B | $305.44B | $292.88B | $308.38B | $281.40B | $275.80B | $241.26B | $253.45B | $253.14B | $249.64B | $238.08B | $248.18B |
| Gross Profit | $727.25B | $639.31B | $658.21B | $481.62B | $731.71B | $699.51B | $737.50B | $646.38B | $760.58B | $696.86B | $679.58B | $564.91B | $619.89B | $569.02B | $708.34B | $516.83B | $583.61B | $539.29B | $563.77B | $523.52B |
| Gross Profit Ratio | 63.56% | 54.40% | 54.50% | 45.80% | 65.80% | 67.10% | 69.70% | 67.60% | 69.40% | 69.50% | 69.90% | 64.70% | 68.80% | 67.40% | 74.60% | 67.10% | 69.75% | 68.36% | 70.31% | 67.84% |
| Research and Development Expenses | $170.19B | $175.56B | $168.46B | $195.86B | $187.38B | $183.95B | $162.74B | $160.94B | $174.63B | $154.15B | $143.61B | $143.63B | $128.38B | $131.60B | $122.48B | $113.29B | $117.57B | $118.16B | $106.82B | $139.31B |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $270.59B | $268.28B | $270.03B | $285.23B | $267.52B | $252.95B | $248.11B | $254.80B | $262.30B | $248.73B | $231.48B | $223.43B | $231.08B | $212.01B | $219.84B | $234.39B | $222.64B | $216.26B | $202.37B | $253.06B |
| Other Expenses | $219.53B | $- | $216.21B | $- | $-1.21B | $- | $- | $- | $-1.01B | $- | $153.98B | $199.47B | $143.95B | $127.98B | $117.46B | $189.57B | $100.26B | $156.58B | $87.29B | $18.99B |
| Operating Expenses | $660.31B | $443.85B | $438.49B | $481.09B | $665.29B | $748.85B | $568.93B | $557.82B | $613.59B | $592.42B | $529.07B | $566.53B | $503.40B | $471.60B | $459.79B | $366.29B | $440.47B | $490.99B | $396.49B | $585.66B |
| Cost and Expenses | $1.08T | $980.57B | $988.28B | $1.05T | $1.04T | $1.09T | $890.05B | $867.59B | $949.56B | $897.87B | $821.95B | $874.91B | $784.81B | $747.39B | $701.05B | $619.73B | $693.61B | $740.63B | $634.57B | $833.84B |
| Interest Income | $-6.99B | $4.12B | $30.68B | $5.99B | $21.79B | $9.36B | $26.45B | $7.78B | $41.68B | $14.78B | $60.92B | $- | $4.14B | $6.86B | $45.85B | $47.49B | $28.40B | $10.02B | $19.61B | $4.59B |
| Interest Expense | $31.60B | $68.45B | $59.69B | $47.19B | $66.57B | $46.52B | $59.58B | $42.93B | $79.75B | $53.80B | $55.47B | $- | $46.71B | $39.68B | $71.07B | $75.24B | $62.67B | $63.87B | $46.85B | $41.05B |
| Depreciation and Amortization | $186.96B | $192.45B | $192.22B | $186.74B | $187.06B | $240.24B | $171.50B | $161.41B | $176.88B | $167.83B | $158.28B | $152.27B | $147.28B | $140.65B | $142.95B | $139.39B | $139.75B | $138.94B | $141.59B | $145.73B |
| EBITDA | $244.96B | $380.28B | $384.55B | $187.28B | $291.98B | $200.26B | $347.90B | $257.76B | $323.87B | $272.26B | $323.04B | $131.41B | $263.77B | $238.07B | $391.55B | $337.42B | $312.21B | $198.09B | $318.72B | $88.73B |
| EBITDA Ratio | 21.41% | 32.34% | 34.10% | 17.82% | 28.34% | 18.29% | 34.58% | 26.38% | 33.18% | 28.55% | 37.97% | 13.89% | 26.29% | 28.62% | 46.02% | 44.86% | 37.31% | 25.11% | 39.75% | 9.07% |
| Operating Income | $66.94B | $184.25B | $219.71B | $534.00M | $104.91B | $-49.34B | $168.57B | $88.56B | $146.99B | $104.44B | $150.51B | $-1.62B | $116.48B | $97.43B | $248.55B | $150.54B | $143.14B | $48.30B | $167.28B | $-62.14B |
| Operating Income Ratio | 5.85% | 15.67% | 18.19% | 0.05% | 9.44% | -4.73% | 15.92% | 9.26% | 13.40% | 10.42% | 15.48% | -0.19% | 12.92% | 11.53% | 26.17% | 19.54% | 17.11% | 6.12% | 20.86% | -8.05% |
| Total Other Income Expenses Net | $-40.53B | $-64.88B | $-82.40B | $-37.45B | $-43.65B | $-46.64B | $-33.54B | $-40.65B | $-39.84B | $-39.89B | $4.96B | $-52.43B | $-44.29B | $-35.98B | $-25.57B | $-19.66B | $-33.34B | $-53.03B | $-36.99B | $-54.63B |
| Income Before Tax | $26.41B | $119.37B | $137.32B | $-51.26B | $61.26B | $-95.98B | $135.03B | $47.91B | $107.15B | $64.55B | $155.47B | $-54.05B | $72.19B | $61.45B | $222.98B | $130.88B | $109.80B | $-4.73B | $130.29B | $-116.76B |
| Income Before Tax Ratio | 2.31% | 10.15% | 11.37% | -4.88% | 5.51% | -9.20% | 12.76% | 5.01% | 9.77% | 6.44% | 15.99% | -6.19% | 8.01% | 7.27% | 23.48% | 16.99% | 13.12% | -0.60% | 16.25% | -15.13% |
| Income Tax Expense | $2.57B | $27.27B | $41.30B | $-44.53B | $-44.50B | $-48.01B | $45.63B | $16.78B | $-12.00B | $2.82B | $50.45B | $-42.67B | $14.37B | $15.45B | $85.25B | $-66.27B | $17.36B | $-8.80B | $47.77B | $-118.32B |
| Net Income | $23.79B | $92.05B | $95.25B | $-3.02B | $105.72B | $-48.03B | $89.39B | $31.13B | $119.13B | $61.74B | $105.01B | $-11.36B | $57.77B | $45.96B | $137.68B | $197.10B | $92.36B | $4.04B | $82.51B | $1.72B |
| Net Income Ratio | 2.08% | 7.83% | 7.88% | -0.29% | 9.51% | -4.60% | 8.44% | 3.26% | 10.86% | 6.16% | 10.80% | -1.30% | 6.41% | 5.44% | 14.50% | 25.59% | 11.04% | 0.51% | 10.29% | 0.22% |
| EPS | $15.03 | $58.14 | $60.71 | $-1.92 | $67.38 | $-30.68 | $57.51 | $20.03 | $76.63 | $39.77 | $67.94 | $-7.31 | $36.91 | $29.24 | $89.08 | $126.07 | $59.08 | $2.58 | $52.93 | $1.11 |
| EPS Diluted | $14.78 | $57.17 | $59.94 | $-1.92 | $66.70 | $-30.68 | $57.12 | $19.29 | $75.86 | $39.48 | $67.56 | $-7.21 | $36.68 | $29.08 | $88.58 | $126.07 | $58.61 | $2.57 | $52.69 | $1.11 |
| Weighted Average Shares Outstanding | 1.58B | 1.58B | 1.57B | 1.57B | 1.57B | 1.57B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.57B | 1.57B | 1.55B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B |
| Weighted Average Shares Outstanding Diluted | 1.61B | 1.61B | 1.59B | 1.57B | 1.59B | 1.57B | 1.57B | 1.61B | 1.57B | 1.56B | 1.55B | 1.58B | 1.57B | 1.58B | 1.55B | 1.56B | 1.58B | 1.57B | 1.57B | 1.56B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $457.80B | $533.53B | $849.70B | $966.22B | $637.61B |
| Short Term Investments | $15.09B | $20.17B | $25.30B | $36.60B | $15.82B |
| Cash and Short Term Investments | $457.80B | $553.70B | $875.00B | $1.00T | $653.44B |
| Net Receivables | $697.61B | $681.69B | $724.38B | $812.71B | $784.92B |
| Inventory | $1.21T | $986.46B | $853.17B | $753.88B | $759.60B |
| Other Current Assets | $193.30B | $196.28B | $166.40B | $180.08B | $287.30B |
| Total Current Assets | $2.56T | $2.40T | $2.59T | $2.71T | $2.47T |
| Property Plant Equipment Net | $1.99T | $1.69T | $1.58T | $1.45T | $1.39T |
| Goodwill | $5.41T | $4.79T | $4.41T | $4.03T | $4.01T |
| Intangible Assets | $4.27T | $4.27T | $3.82T | $3.91T | $4.17T |
| Goodwill and Intangible Assets | $9.68T | $9.06T | $8.23T | $7.94T | $8.18T |
| Long Term Investments | $430.61B | $378.86B | $330.13B | $348.35B | $369.45B |
| Tax Assets | $393.87B | $366.00B | $362.54B | $353.77B | $308.10B |
| Other Non-Current Assets | $51.21B | $63.33B | $82.61B | $100.34B | $103.85B |
| Total Non-Current Assets | $12.55T | $11.56T | $10.58T | $10.20T | $10.35T |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $15.11T | $13.96T | $13.18T | $12.91T | $12.82T |
| Account Payables | $319.95B | $307.45B | $295.93B | $232.10B | $211.63B |
| Short Term Debt | $367.25B | $399.22B | $257.87B | $72.34B | $627.90B |
| Tax Payables | $109.91B | $232.38B | $200.92B | $145.20B | $182.74B |
| Deferred Revenue | $- | $740.74B | $644.42B | $616.48B | $587.98B |
| Other Current Liabilities | $1.52T | $1.54T | $1.39T | $1.32T | $1.15T |
| Total Current Liabilities | $2.31T | $2.48T | $2.15T | $1.77T | $2.18T |
| Long Term Debt | $5.03T | $4.46T | $4.55T | $5.00T | $4.83T |
| Deferred Revenue Non-Current | $- | $208.12B | $219.68B | $231.29B | $249.15B |
| Deferred Tax Liabilities Non-Current | $113.78B | $270.62B | $451.51B | $542.85B | $710.15B |
| Other Non-Current Liabilities | $377.98B | $179.93B | $124.80B | $188.35B | $123.55B |
| Total Non-Current Liabilities | $5.52T | $5.12T | $5.35T | $5.96T | $5.92T |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $7.83T | $7.60T | $7.49T | $7.74T | $8.09T |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.68T | $1.68T | $1.68T | $1.67T | $1.67T |
| Retained Earnings | $1.39T | $1.54T | $1.48T | $1.51T | $1.37T |
| Accumulated Other Comprehensive Income Loss | $2.51T | $1.51T | $934.17B | $366.11B | $92.56B |
| Other Total Stockholders Equity | $1.70T | $1.63T | $1.59T | $1.63T | $1.59T |
| Total Stockholders Equity | $7.27T | $6.35T | $5.68T | $5.17T | $4.72T |
| Total Equity | $7.27T | $6.35T | $5.68T | $5.18T | $4.73T |
| Total Liabilities and Stockholders Equity | $15.11T | $13.96T | $13.18T | $12.91T | $12.82T |
| Minority Interest | $741.00M | $549.00M | $504.00M | $4.14B | $4.00B |
| Total Liabilities and Total Equity | $15.11T | $13.96T | $13.18T | $12.91T | $12.82T |
| Total Investments | $445.70B | $99.17B | $96.58B | $112.47B | $107.33B |
| Total Debt | $4.84T | $4.38T | $4.35T | $4.64T | $5.09T |
| Net Debt | $4.39T | $3.85T | $3.50T | $3.67T | $4.46T |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $494.13B | $859.01B | $804.27B | $457.80B | $288.36B | $318.05B | $316.38B | $533.53B | $685.14B | $798.14B | $645.99B | $849.70B | $724.34B | $607.88B | $654.92B | $966.22B | $617.63B | $630.87B | $589.79B | $637.61B |
| Short Term Investments | $32.62B | $47.20B | $53.39B | $15.09B | $29.05B | $15.76B | $52.23B | $20.17B | $41.47B | $31.93B | $18.54B | $25.30B | $27.55B | $25.74B | $29.93B | $36.60B | $36.66B | $15.31B | $11.14B | $15.82B |
| Cash and Short Term Investments | $526.75B | $906.22B | $804.27B | $457.80B | $317.40B | $333.81B | $368.61B | $553.70B | $726.61B | $830.07B | $664.53B | $875.00B | $751.90B | $633.62B | $684.85B | $1.00T | $654.30B | $646.18B | $600.92B | $653.44B |
| Net Receivables | $735.06B | $721.06B | $772.37B | $697.61B | $743.08B | $788.07B | $825.48B | $681.69B | $779.87B | $800.54B | $794.09B | $724.38B | $756.12B | $887.29B | $858.96B | $812.71B | $828.94B | $769.81B | $815.27B | $784.92B |
| Inventory | $1.25T | $1.21T | $1.28T | $1.21T | $1.17T | $1.16T | $1.08T | $986.46B | $927.29B | $953.45B | $927.51B | $853.17B | $811.32B | $783.48B | $779.15B | $753.88B | $739.35B | $743.48B | $759.38B | $759.60B |
| Other Current Assets | $246.05B | $220.31B | $254.15B | $193.30B | $227.75B | $200.08B | $246.78B | $196.28B | $203.65B | $193.49B | $181.92B | $166.40B | $186.11B | $177.70B | $183.43B | $180.08B | $430.67B | $440.98B | $310.33B | $287.30B |
| Total Current Assets | $2.75T | $3.05T | $3.11T | $2.56T | $2.43T | $2.46T | $2.47T | $2.40T | $2.60T | $2.75T | $2.55T | $2.59T | $2.48T | $2.46T | $2.48T | $2.71T | $2.62T | $2.59T | $2.47T | $2.47T |
| Property Plant Equipment Net | $2.02T | $1.89T | $2.09T | $1.99T | $1.84T | $1.89T | $1.80T | $1.69T | $1.66T | $1.76T | $1.71T | $1.58T | $1.49T | $1.46T | $1.45T | $1.45T | $1.36T | $1.37T | $1.37T | $1.39T |
| Goodwill | $5.52T | $5.16T | $5.73T | $5.41T | $5.11T | $5.30T | $5.18T | $4.79T | $4.69T | $4.99T | $4.81T | $4.41T | $4.17T | $4.08T | $4.06T | $4.03T | $3.82T | $3.86T | $3.98T | $4.01T |
| Intangible Assets | $3.95T | $3.77T | $4.37T | $4.27T | $4.10T | $4.40T | $4.51T | $4.27T | $3.77T | $4.19T | $4.15T | $3.82T | $3.79T | $3.78T | $3.86T | $3.91T | $3.76T | $3.88T | $4.04T | $4.17T |
| Goodwill and Intangible Assets | $9.47T | $8.93T | $10.10T | $9.68T | $9.21T | $9.70T | $9.70T | $9.06T | $8.46T | $9.18T | $8.96T | $8.23T | $7.96T | $7.86T | $7.92T | $7.94T | $7.58T | $7.73T | $8.03T | $8.18T |
| Long Term Investments | $410.21B | $277.31B | $447.18B | $430.61B | $372.92B | $416.36B | $393.53B | $378.86B | $369.47B | $425.77B | $381.61B | $330.13B | $334.81B | $352.09B | $374.66B | $348.35B | $376.05B | $349.60B | $336.64B | $369.45B |
| Tax Assets | $376.26B | $338.30B | $381.63B | $393.87B | $316.69B | $336.21B | $375.52B | $366.00B | $359.39B | $394.75B | $385.56B | $362.54B | $352.71B | $335.57B | $343.56B | $353.77B | $252.25B | $278.43B | $305.83B | $308.10B |
| Other Non-Current Assets | $74.16B | $85.02B | $106.10B | $51.21B | $54.70B | $59.67B | $60.14B | $63.33B | $66.77B | $80.70B | $84.68B | $82.61B | $79.64B | $94.29B | $95.02B | $100.34B | $96.57B | $100.23B | $103.02B | $103.85B |
| Total Non-Current Assets | $12.35T | $11.52T | $13.12T | $12.55T | $11.79T | $12.41T | $12.32T | $11.56T | $10.91T | $11.84T | $11.52T | $10.58T | $10.22T | $10.10T | $10.18T | $10.20T | $9.67T | $9.83T | $10.14T | $10.35T |
| Other Assets | $2.00M | $- | $- | $- | $-1.00M | $2.00M | $- | $- | $1.00M | $- | $1.00M | $- | $-1.00M | $- | $-1.00M | $- | $- | $- | $- | $- |
| Total Assets | $15.11T | $14.57T | $16.23T | $15.11T | $14.22T | $14.87T | $14.79T | $13.96T | $13.50T | $14.59T | $14.07T | $13.18T | $12.70T | $12.56T | $12.66T | $12.91T | $12.29T | $12.41T | $12.61T | $12.82T |
| Account Payables | $460.18B | $413.33B | $468.88B | $319.95B | $483.67B | $421.08B | $440.92B | $75.08B | $381.11B | $388.62B | $424.36B | $295.93B | $351.19B | $336.60B | $320.64B | $86.90B | $326.98B | $272.78B | $289.74B | $28.89B |
| Short Term Debt | $135.47B | $624.10B | $438.74B | $367.25B | $370.29B | $274.84B | $416.86B | $399.22B | $372.02B | $568.23B | $281.90B | $257.87B | $122.94B | $214.89B | $24.27B | $72.34B | $284.47B | $276.62B | $580.73B | $627.90B |
| Tax Payables | $159.45B | $141.44B | $162.20B | $109.91B | $112.45B | $130.22B | $242.76B | $232.38B | $188.78B | $189.57B | $249.43B | $200.92B | $185.44B | $188.06B | $200.93B | $145.20B | $135.80B | $144.71B | $179.51B | $182.74B |
| Deferred Revenue | $- | $- | $162.20B | $109.91B | $594.91B | $787.88B | $770.53B | $740.74B | $661.97B | $674.31B | $714.36B | $644.42B | $606.92B | $603.14B | $611.23B | $616.48B | $597.51B | $602.28B | $604.16B | $587.98B |
| Other Current Liabilities | $1.34T | $1.21T | $1.23T | $1.41T | $720.85B | $753.61B | $630.67B | $1.78T | $632.93B | $571.00B | $496.89B | $1.39T | $542.77B | $576.06B | $549.71B | $1.47T | $460.19B | $413.28B | $377.40B | $1.34T |
| Total Current Liabilities | $2.10T | $2.39T | $2.47T | $2.31T | $2.28T | $2.37T | $2.50T | $2.48T | $2.24T | $2.39T | $2.17T | $2.15T | $1.81T | $1.92T | $1.71T | $1.77T | $1.80T | $1.71T | $2.03T | $2.18T |
| Long Term Debt | $4.70T | $4.43T | $5.66T | $5.03T | $4.84T | $4.98T | $4.83T | $4.46T | $4.42T | $4.72T | $4.83T | $4.55T | $4.23T | $4.02T | $4.16T | $5.00T | $4.96T | $5.11T | $4.90T | $4.83T |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $156.66B | $153.94B | $201.42B | $208.12B | $217.59B | $230.83B | $222.26B | $219.68B | $234.72B | $229.61B | $225.85B | $231.29B | $255.48B | $246.00B | $250.93B | $249.15B |
| Deferred Tax Liabilities Non-Current | $37.67B | $46.62B | $55.51B | $113.78B | $133.04B | $228.72B | $269.55B | $270.62B | $388.68B | $465.75B | $456.81B | $451.51B | $558.61B | $547.35B | $549.06B | $542.85B | $575.97B | $636.85B | $686.38B | $710.15B |
| Other Non-Current Liabilities | $847.34B | $790.46B | $249.11B | $377.98B | $72.47B | $71.36B | $72.61B | $179.93B | $66.70B | $70.30B | $72.82B | $124.80B | $532.18B | $523.73B | $555.31B | $188.35B | $48.43B | $47.72B | $53.85B | $123.55B |
| Total Non-Current Liabilities | $5.59T | $5.26T | $5.96T | $5.52T | $5.20T | $5.43T | $5.37T | $5.12T | $5.09T | $5.48T | $5.58T | $5.35T | $5.56T | $5.32T | $5.71T | $5.96T | $5.84T | $6.04T | $5.89T | $5.92T |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $7.69T | $7.65T | $8.43T | $7.83T | $7.48T | $7.80T | $7.87T | $7.60T | $7.33T | $7.88T | $7.75T | $7.49T | $7.37T | $7.24T | $7.42T | $7.74T | $7.65T | $7.75T | $7.92T | $8.09T |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.69T | $1.69T | $1.68T | $1.68T | $1.68T | $1.68T | $1.68T | $1.68T | $1.68T | $1.68T | $1.68T | $1.68T | $1.68T | $1.68T | $1.67T | $1.67T | $1.67T | $1.67T | $1.67T | $1.67T |
| Retained Earnings | $1.29T | $1.43T | $1.34T | $1.39T | $1.40T | $1.45T | $1.49T | $1.54T | $1.51T | $1.53T | $1.46T | $1.48T | $1.47T | $1.55T | $1.50T | $1.51T | $1.31T | $1.34T | $1.33T | $1.37T |
| Accumulated Other Comprehensive Income Loss | $- | $2.08T | $3.08T | $2.51T | $1.99T | $2.29T | $2.11T | $1.51T | $1.38T | $1.91T | $1.60T | $934.17B | $584.27B | $451.07B | $425.16B | $366.11B | $41.55B | $47.88B | $87.81B | $92.56B |
| Other Total Stockholders Equity | $4.43T | $1.71T | $1.71T | $1.70T | $1.68T | $1.66T | $1.64T | $1.63T | $1.61T | $1.60T | $1.58T | $1.59T | $1.60T | $1.65T | $1.64T | $1.63T | $1.62T | $1.61T | $1.60T | $1.59T |
| Total Stockholders Equity | $7.42T | $6.92T | $7.80T | $7.27T | $6.74T | $7.07T | $6.92T | $6.35T | $6.18T | $6.71T | $6.32T | $5.68T | $5.33T | $5.32T | $5.24T | $5.17T | $4.64T | $4.66T | $4.69T | $4.72T |
| Total Equity | $7.42T | $6.92T | $7.80T | $7.27T | $6.74T | $7.07T | $6.92T | $6.35T | $6.18T | $6.71T | $6.32T | $5.68T | $5.33T | $5.32T | $5.24T | $5.18T | $4.64T | $4.67T | $4.69T | $4.73T |
| Total Liabilities and Stockholders Equity | $15.11T | $14.57T | $16.23T | $15.11T | $14.22T | $14.87T | $14.79T | $13.96T | $13.50T | $14.59T | $14.07T | $13.18T | $12.70T | $12.56T | $12.66T | $12.91T | $12.29T | $12.41T | $12.61T | $12.82T |
| Minority Interest | $917.00M | $843.00M | $815.00M | $741.00M | $673.00M | $673.00M | $617.00M | $549.00M | $520.00M | $560.00M | $551.00M | $504.00M | $493.00M | $426.00M | $385.00M | $4.14B | $4.08B | $4.10B | $4.00B | $4.00B |
| Total Liabilities and Total Equity | $15.11T | $14.57T | $16.23T | $15.11T | $14.22T | $14.87T | $14.79T | $13.96T | $13.50T | $14.59T | $14.07T | $13.18T | $12.70T | $12.56T | $12.66T | $12.91T | $12.29T | $12.41T | $12.61T | $12.82T |
| Total Investments | $442.83B | $324.51B | $447.18B | $430.61B | $401.96B | $432.12B | $100.42B | $399.03B | $410.94B | $457.70B | $97.09B | $96.58B | $104.51B | $115.25B | $404.59B | $384.95B | $412.71B | $364.92B | $347.78B | $385.28B |
| Total Debt | $4.84T | $5.05T | $5.48T | $4.84T | $4.66T | $4.68T | $4.75T | $4.38T | $4.29T | $4.74T | $4.60T | $4.35T | $4.35T | $4.23T | $4.41T | $4.64T | $4.75T | $4.91T | $5.07T | $5.09T |
| Net Debt | $4.35T | $4.19T | $4.68T | $4.39T | $4.38T | $4.36T | $4.43T | $3.85T | $3.60T | $3.94T | $3.96T | $3.50T | $3.63T | $3.62T | $3.75T | $3.67T | $4.13T | $4.28T | $4.49T | $4.46T |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $144.07B | $317.04B | $230.17B | $376.17B | $44.29B |
| Depreciation and Amortization | $728.00B | $664.40B | $583.15B | $559.67B | $583.65B |
| Deferred Income Tax | $-91.41B | $58.05B | $72.41B | $-9.94B | $-105.04B |
| Stock Based Compensation | $70.87B | $60.67B | $43.37B | $37.66B | $29.12B |
| Change in Working Capital | $-256.00B | $-25.26B | $98.61B | $275.78B | $94.67B |
| Accounts Receivables | $15.10B | $75.13B | $127.29B | $-9.32B | $-34.83B |
| Inventory | $-115.74B | $-79.16B | $-46.15B | $25.98B | $137.49B |
| Accounts Payables | $-9.89B | $-53.13B | $75.55B | $210.02B | $-29.93B |
| Other Working Capital | $-145.47B | $31.90B | $-58.09B | $49.10B | $21.94B |
| Other Non Cash Items | $120.81B | $-97.74B | $95.40B | $-228.42B | $23.06B |
| Net Cash Provided by Operating Activities | $716.34B | $977.16B | $1.12T | $1.01T | $669.75B |
| Investments in Property Plant and Equipment | $-175.42B | $-633.69B | $-186.04B | $-236.47B | $-217.71B |
| Acquisitions Net | $-4.74B | $7.96B | $-21.48B | $530.39B | $456.66B |
| Purchases of Investments | $-40.07B | $-10.15B | $-8.34B | $-12.60B | $-7.55B |
| Sales Maturities of Investments | $8.02B | $22.25B | $16.92B | $74.60B | $49.40B |
| Other Investing Activities | $-251.66B | $6.53B | $808.00M | $37.60B | $11.32B |
| Net Cash Used for Investing Activities | $-463.86B | $-607.10B | $-198.12B | $393.53B | $292.12B |
| Debt Repayment | $1.51B | $-325.07B | $-600.48B | $-656.06B | $-586.09B |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-2.33B | $-26.93B | $-77.53B | $-2.14B | $-3.74B |
| Dividends Paid | $-287.19B | $-279.42B | $-283.67B | $-283.36B | $-282.58B |
| Other Financing Activities | $-66.42B | $-77.73B | $-108.59B | $-146.79B | $-132.80B |
| Net Cash Used Provided by Financing Activities | $-354.42B | $-709.15B | $-1.07T | $-1.09T | $-1.01T |
| Effect of Forex Changes on Cash | $26.20B | $22.93B | $28.76B | $12.50B | $-21.77B |
| Net Change in Cash | $-75.73B | $-316.17B | $-116.53B | $328.61B | $-65.11B |
| Cash at End of Period | $457.80B | $533.53B | $849.70B | $966.22B | $637.61B |
| Cash at Beginning of Period | $533.53B | $849.70B | $966.22B | $637.61B | $702.72B |
| Operating Cash Flow | $716.34B | $977.16B | $1.12T | $1.01T | $669.75B |
| Capital Expenditure | $-480.73B | $-633.69B | $-186.04B | $-236.47B | $-217.71B |
| Free Cash Flow | $235.61B | $343.47B | $937.07B | $774.46B | $452.04B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $23.84B | $92.05B | $95.25B | $-3.02B | $105.75B | $-47.97B | $89.41B | $31.14B | $119.15B | $61.73B | $105.02B | $-11.38B | $57.82B | $45.99B | $137.73B | $197.14B | $92.44B | $4.07B | $82.52B | $1.56B |
| Depreciation and Amortization | $186.96B | $192.45B | $192.22B | $186.74B | $187.06B | $182.70B | $171.50B | $161.41B | $176.88B | $167.83B | $158.28B | $152.27B | $147.28B | $140.65B | $142.95B | $139.39B | $139.75B | $138.94B | $141.59B | $145.73B |
| Deferred Income Tax | $2.57B | $- | $41.30B | $-44.53B | $-44.50B | $-48.01B | $45.63B | $16.78B | $-12.00B | $2.82B | $50.45B | $-42.67B | $14.37B | $15.45B | $85.25B | $-66.27B | $17.36B | $-8.80B | $47.77B | $-118.32B |
| Stock Based Compensation | $18.30B | $- | $15.39B | $18.19B | $18.71B | $18.54B | $15.44B | $14.85B | $16.49B | $17.04B | $12.29B | $11.32B | $11.09B | $12.43B | $8.55B | $9.54B | $10.02B | $8.05B | $10.04B | $7.91B |
| Change in Working Capital | $88.76B | $-80.45B | $-189.98B | $99.06B | $-166.02B | $1.59B | $-150.95B | $143.39B | $51.30B | $-31.49B | $-188.47B | $178.68B | $71.61B | $9.21B | $-160.90B | $257.87B | $1.29B | $67.81B | $-51.19B | $76.03B |
| Accounts Receivables | $12.67B | $-10.04B | $-47.74B | $73.90B | $14.29B | $17.29B | $-90.37B | $68.27B | $12.77B | $12.05B | $-17.97B | $45.05B | $137.43B | $-13.36B | $-49.82B | $40.59B | $-48.37B | $24.30B | $-25.84B | $34.09B |
| Inventory | $21.24B | $-41.14B | $-10.08B | $12.75B | $-50.55B | $-49.35B | $-28.59B | $-44.91B | $-18.46B | $-6.66B | $-9.12B | $-6.88B | $-14.30B | $-3.96B | $-21.01B | $19.92B | $3.05B | $7.38B | $-4.37B | $44.75B |
| Accounts Payables | $- | $376.00M | $-37.45B | $-30.48B | $70.27B | $-15.02B | $-9.40B | $60.17B | $-7.71B | $-40.14B | $-141.28B | $128.50B | $-44.94B | $24.82B | $-24.85B | $- | $21.25B | $-3.18B | $-23.15B | $- |
| Other Working Capital | $54.85B | $-29.65B | $-94.70B | $42.90B | $-200.02B | $48.67B | $-22.58B | $59.87B | $64.71B | $3.25B | $-20.11B | $12.01B | $-51.52B | $26.52B | $-65.22B | $237.95B | $25.35B | $39.31B | $2.18B | $31.28B |
| Other Non Cash Items | $63.34B | $54.95B | $541.60B | $307.01B | $45.45B | $92.06B | $-78.63B | $-73.87B | $26.40B | $3.06B | $-53.34B | $87.36B | $45.34B | $9.42B | $-46.72B | $-136.72B | $-42.90B | $36.07B | $-84.87B | $72.53B |
| Net Cash Provided by Operating Activities | $383.76B | $259.00B | $159.38B | $272.47B | $146.45B | $198.91B | $92.40B | $293.69B | $378.23B | $220.99B | $84.24B | $375.58B | $347.51B | $233.15B | $166.86B | $400.96B | $217.96B | $246.15B | $145.86B | $185.44B |
| Investments in Property Plant and Equipment | $-45.09B | $-60.67B | $-137.80B | $-64.33B | $-77.12B | $-70.04B | $-269.24B | $-444.08B | $-50.62B | $-40.61B | $-98.38B | $-51.82B | $-48.43B | $-43.49B | $-42.29B | $-111.96B | $-43.62B | $-40.41B | $-40.48B | $-62.88B |
| Acquisitions Net | $1.26B | $5.42B | $2.95B | $-13.70B | $-26.25B | $-7.00M | $372.00M | $7.96B | $-15.02B | $-7.99B | $-55.61B | $26.06B | $-22.12B | $-10.64B | $-25.41B | $405.42B | $93.57B | $31.40B | $-16.83B | $85.71B |
| Purchases of Investments | $-67.57B | $-10.05B | $-12.98B | $-2.04B | $-2.46B | $-1.59B | $-674.00M | $-4.71B | $-747.00M | $-1.76B | $-2.93B | $-741.00M | $-4.01B | $-340.00M | $-3.25B | $-3.12B | $-3.26B | $-2.70B | $-3.52B | $-224.00M |
| Sales Maturities of Investments | $3.56B | $17.80B | $5.32B | $6.93B | $458.00M | $88.00M | $543.00M | $1.70B | $2.15B | $12.22B | $6.18B | $856.00M | $6.00B | $9.59B | $483.00M | $887.00M | $23.07B | $6.21B | $44.44B | $1.61B |
| Other Investing Activities | $-7.72B | $-32.49B | $-18.72B | $-3.92B | $30.11B | $10.97B | $2.47B | $639.00M | $17.55B | $10.93B | $56.03B | $12.00M | $-21.93B | $-11.39B | $26.00M | $2.10B | $2.22B | $33.07B | $17.05B | $12.04B |
| Net Cash Used for Investing Activities | $-115.56B | $-80.00B | $-161.23B | $-77.06B | $-75.27B | $-60.58B | $-266.53B | $-438.49B | $-46.69B | $-27.21B | $-94.71B | $-25.64B | $-69.14B | $-32.90B | $-70.44B | $293.33B | $71.97B | $27.56B | $662.00M | $36.24B |
| Debt Repayment | $-470.88B | $-57.09B | $440.53B | $-11.28B | $-96.51B | $-157.07B | $99.37B | $29.02B | $-266.20B | $-10.77B | $-37.13B | $-184.86B | $45.99B | $-208.36B | $-253.25B | $-326.65B | $-135.40B | $-190.88B | $-27.19B | $-103.89B |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $-1.88B | $- | $- | $- | $-2.33B | $- | $- | $- | $-26.93B | $-24.99B | $-50.00B | $- | $-2.54B | $-3.00M | $-3.00M | $-3.00M | $-2.13B | $-12.00M |
| Dividends Paid | $-145.45B | $-9.20B | $-138.11B | $-9.13B | $-138.25B | $-9.06B | $-130.75B | $-10.42B | $-128.99B | $-11.13B | $-128.87B | $-10.64B | $-131.45B | $-9.54B | $-132.03B | $-8.68B | $-132.93B | $-8.64B | $-133.12B | $-8.32B |
| Other Financing Activities | $-39.64B | $-16.93B | $31.31B | $-37.82B | $137.00B | $25.48B | $-24.07B | $-25.20B | $-39.77B | $-29.98B | $-22.79B | $-23.31B | $-32.60B | $-29.46B | $-23.22B | $-34.74B | $-31.74B | $-25.92B | $-30.33B | $-31.71B |
| Net Cash Used Provided by Financing Activities | $-655.97B | $-83.21B | $331.85B | $-36.53B | $-97.76B | $-140.66B | $-57.78B | $-6.60B | $-434.95B | $-51.88B | $-215.72B | $-243.80B | $-168.06B | $-247.37B | $-411.04B | $-370.07B | $-300.07B | $-225.44B | $-192.76B | $-143.93B |
| Effect of Forex Changes on Cash | $22.88B | $-41.78B | $17.22B | $10.56B | $-3.12B | $4.00B | $14.76B | $-212.00M | $-9.58B | $10.23B | $22.48B | $19.21B | $6.15B | $78.00M | $3.32B | $24.30B | $-3.23B | $-6.99B | $-1.58B | $-8.42B |
| Net Change in Cash | $-364.89B | $54.74B | $599.08B | $169.44B | $-29.69B | $1.67B | $-217.15B | $-151.61B | $-113.00B | $152.15B | $-203.70B | $125.35B | $116.46B | $-47.04B | $-311.30B | $348.59B | $-13.23B | $41.08B | $-47.83B | $69.33B |
| Cash at End of Period | $494.13B | $859.01B | $804.27B | $457.80B | $288.36B | $318.05B | $316.38B | $533.53B | $685.14B | $798.14B | $645.99B | $849.70B | $724.34B | $607.88B | $654.92B | $966.22B | $617.63B | $630.87B | $589.79B | $637.61B |
| Cash at Beginning of Period | $859.01B | $804.27B | $205.19B | $288.36B | $318.05B | $316.38B | $533.53B | $685.14B | $798.14B | $645.99B | $849.70B | $724.34B | $607.88B | $654.92B | $966.22B | $617.63B | $630.87B | $589.79B | $637.61B | $568.28B |
| Operating Cash Flow | $383.76B | $259.00B | $159.38B | $272.47B | $146.45B | $198.91B | $92.40B | $293.69B | $378.23B | $220.99B | $84.24B | $375.58B | $347.51B | $233.15B | $166.86B | $400.96B | $217.96B | $246.15B | $145.86B | $185.44B |
| Capital Expenditure | $-56.65B | $-49.47B | $-137.80B | $-64.33B | $-77.12B | $-70.04B | $-269.24B | $-444.08B | $-50.62B | $-40.61B | $-98.38B | $-51.82B | $-48.43B | $-43.49B | $-42.29B | $-111.96B | $-43.62B | $-40.41B | $-40.48B | $-62.88B |
| Free Cash Flow | $327.11B | $209.53B | $21.58B | $208.15B | $69.33B | $128.86B | $-176.84B | $-150.39B | $327.61B | $180.38B | $-14.13B | $323.76B | $299.08B | $189.66B | $124.57B | $289.00B | $174.34B | $205.74B | $105.38B | $122.55B |
Takeda Pharmaceutical Dividends
Explore Takeda Pharmaceutical's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
4.41%
Dividend Payout Ratio
199.34%
Dividend Paid & Capex Coverage Ratio
0.93x
Takeda Pharmaceutical Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $98 | $98 | March 28, 2025 | March 31, 2025 | June 01, 2025 | |
| $98 | $98 | September 27, 2024 | September 30, 2024 | December 02, 2024 | |
| $94 | $94 | March 28, 2024 | March 31, 2024 | June 27, 2024 | |
| $94 | $94 | September 28, 2023 | September 30, 2023 | December 01, 2023 | |
| $90 | $90 | March 30, 2023 | March 31, 2023 | June 29, 2023 | |
| $90 | $90 | September 29, 2022 | September 30, 2022 | December 01, 2022 | |
| $90 | $90 | March 30, 2022 | March 31, 2022 | June 30, 2022 | |
| $90 | $90 | September 29, 2021 | September 30, 2021 | December 01, 2021 | |
| $90 | $90 | March 30, 2021 | March 31, 2021 | June 30, 2021 | |
| $90 | $90 | September 29, 2020 | September 30, 2020 | December 01, 2020 | |
| $90 | $90 | March 30, 2020 | March 31, 2020 | June 25, 2020 | |
| $90 | $90 | September 27, 2019 | September 30, 2019 | December 02, 2019 | |
| $90 | $90 | March 27, 2019 | March 31, 2019 | June 28, 2019 | |
| $90 | $90 | September 26, 2018 | September 30, 2018 | December 03, 2018 | |
| $90 | $90 | March 28, 2018 | March 31, 2018 | June 29, 2018 | |
| $90 | $90 | September 27, 2017 | September 30, 2017 | December 01, 2017 | |
| $90 | $90 | March 29, 2017 | March 31, 2017 | June 29, 2017 | |
| $90 | $90 | September 28, 2016 | |||
| $90 | $90 | March 29, 2016 | |||
| $90 | $90 | September 28, 2015 |
Takeda Pharmaceutical News
Read the latest news about Takeda Pharmaceutical, including recent articles, headlines, and updates.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for 4502.T.